Dinutuximab beta
Unituxin, Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron) (dinutuximab) is an antibody pharmaceutical. Dinutuximab was first approved as Unituxin on 2017-05-08. It is used to treat neuroblastoma in the USA. It has been approved in Europe to treat neuroblastoma.
| Trade Name | Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron) |
|---|---|
| Common Name | Dinutuximab beta |
| Indication | neuroblastoma |
| Drug Class | Monoclonal antibodies: chimeric, tumors as target |
